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Structured Abstract 
Introduction 
Physicians have long worried about gene patents’ potential to restrict their medical practices. 
Fortune and hindsight have proven these worries exaggerated both in the U.K. and elsewhere. Neither 
current nor future medical practices appear to be impinged by gene patents, although they may be 
subject to future intellectual property disputes. 
Sources of Data 
Qualitative and quantitative (survey) studies of gene patents’ effects on medical practice; recent 
developments in patent law. 
Areas of Agreement 
Traditional gene patents do not appear to have restricted medical practice in the U.K., although 
their effect elsewhere has been more nuanced. 
Areas of Controversy 
Whether patents will restrict the spread of newer medical technologies is unresolved. 
Areas Timely for Developing Research 
Continuing survey data on practitioners’ views concerning patents’ role in the distribution of 
newer technologies would be beneficial. 
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Introduction 
The specter of “gene patents” interfering with medical practice has long haunted 
clinicians.1 For over a decade, physicians have fretted over the possibility that corporate 
ownership of human genes, through patents, would restrict doctors’ ability to diagnose and 
treat their patients.2 In 2013, these fears were heightened in the run-up to the Myriad Genetics 
case before the Supreme Court of the United States, a case concerning the patenting of BRCA1 
and 2, genes of critical importance in assessing early-onset breast and ovarian cancer risk.3 
Today—with both fortune and hindsight—such seem exaggerated. The weight of 
evidence, both empirical and qualitative, have found that “gene patents”—an amorphous 
term, not readily subject to definition—have not affected the practice of medicine in the 
U.K.1-2,4 Gene patents covering medically important tests have frequently been licensed 
cheaply and easily.5 In other instances, gene patents have been invalidated by courts or patent 
offices; genetic technology has advanced to the point where it is no longer covered by 
traditional gene patents; or clinicians have simply ignored patents in their field.2-3,6 In 
addition, many jurisdictions—such as the United States and Australia—have placed 
restrictions on patentable genetic subject matter.3,7 At the same time, genetic diagnostics 
appear to be developing and rapidly integrated into in the medical landscape, despite patent 
protection—or, in some cases, the lack thereof.6 
Gene patents’ muted effect on medical practice is a complex function of law, history, 
technological development, and medical mores. Whether such an effect will remain muted is 
uncertain. New, medically significant genetic technologies, like whole genome sequencing, 
precision medicine, and genetic engineering are similarly being integrated into medical 
practice while being covered by patent protection. This review examines what constitutes a 
“gene patent,” gene patents’ current legal status in the U.K. and the rest of the world, and their 
present—and potential future—effects on medical practice. 
Defining “Gene Patent” 
Despite common use of the term, it is difficult to clearly define what constitutes a “gene 
patent.” Many patents describe or lay claim to genetic sequences, but often do so in relation to 
other technical inventions having little to do with the underlying sequences themselves.8 
Others claim genetic material that is either synthetic—that is, recombinant—or significantly 
modified from the natural products from which they derives.5 Further, neither the Intellectual 
Property Office nor the European Patent Office labels patents as “gene patents.” Referring to a 
patent as a “gene patent” is more of a lay term—or, frequently, an anti-normative sentiment—
than it is a well understood term to patent attorneys. 
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Nonetheless, when the public refers to “gene patents,” it is likely circumscribing a 
population of patents that claim, as their principal invention, a naturally occurring or 
insignificantly modified nucleic acid.1,5 That is, the likely best definition of a “gene patent” is 
one that claims a naturally occurring gene or allele or some significant portion thereof. This 
understanding of “gene patent” has some basis in patent law. Today, patent offices throughout 
the world have established a set of international protocols for submitting sequences of nucleic 
acids, known as “sequence listings.” For example, the most recent version of The Patents 
Rules, the secondary legislation that complements the U.K.’s 1977 Patents Act, require a 
sequence listing for any patent “[w]here the specification of an application discloses a 
sequence.”9 Similarly, Rule 30 of the European Patent Convention requires sequence listings 
“conforming to the rules laid down by the President of the European Patent Office for the 
standardised representation of nucleotide and amino acid sequences.”10 At a minimum, gene 
patents are likely those that come with sequence listings. 
These efforts at standardization aside, defining gene patents by reference to their 
inclusion of naturally occurring sequences belies greater complexities about the genetic code. 
How much of a naturally occurring gene is required for a patent to become a gene patent? How 
should unintentional redundancy—a synthetic sequence’s overlap with a natural one—be 
treated? And, like the ship of Theseus—rebuilt plank by plank until none of its original 
boards remained—how much alteration of a naturally occurring sequence is required for a 
gene patent to become, simply, a patent claiming a man-made genetic sequence? Different 
jurisdictions have answered these questions differently, and however “gene patent” is to be 
defined, the term will always be fraught will some degree of ambiguity. 
The Patentability of Genes 
Many physicians think of gene patents as a relative recent phenomena, which is 
understandable given the attention gene patents received in the late 1990s and the early 2000s 
together with the Human Genome Project.2 But genetic material has been the subject of 
patents since at least the 1960s when researchers began to receive U.S. patents on naturally 
occurring RNA sequences. With the advent of recombinant DNA in the 1970s and 1980s, 
researchers also began to receive patents covering recombinant DNA—most famously, 
Herbert W. Boyer and Stanley Cohen’s 1980 patent, widely seen as a watershed moment in 
biotechnology. In 1981, the first patent claiming a naturally occurring genetic sequence was 
awarded in the United States: a patent covering a naturally occurring yeast plasmid.5 
In tandem with the advent of large scale sequencing of the human genome, researchers—
both at public and private institutions—began to obtain patents on isolated human genes by 
the thousands. Such patents famously included clinically significant genes, like HFE, a gene 
implicated in hereditary haemochromatosis; CFTR, the cystic fibrosis gene; and, of course, 
BRCA1 and BRCA2, the breast- and ovarian-cancer risk genes.11 Patents at the time also 
included fragments of expressed mRNA, also known as “expressed sequence tags”—a strategy 
finally outlawed in the United States in 2005. Since that time, there has been disagreement as 
to how much of the human genome was ultimately the subject of patent protection, although 
early upper estimates that, for example, 90% of the human genome was patented, are almost 
certainly incorrect.8 
Despite the widespread nature of gene patents in the early 2000s, there were few reported 
instances of these patents impinging on physicians’ autonomy to test, diagnose, and treat their 
patients. An influential 2002 report from the Nuffield Council on Bioethics found that patents 
covering genes related to HIV, hepatitis B and C, and the MSP-1 malaria protein were mostly 
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unobjectionable because they were used to broadly license diagnostic tests in aid of diagnoses 
and treatment. The Council ultimately concluded that gene patents were, “in the main, 
defensible . . . [but] that in the particular case of patents that assert property rights over DNA, 
consideration should be given to whether the balance between public and private interests 
has been fairly struck.”1 Other, later empirical studies came to similar conclusions.2,4 
While gene patents did not appear to interfere with physician autonomy, they did—at 
least initially—dampen patient choice and access to tests outside Britain. A 2003 empirical 
study found that while specific patent demands were rare, U.S. clinicians were nonetheless 
fearful that gene patents would stymie their work.12 This was followed, in 2010, by an 
influential report in the United States concluding that, in several, isolated incidences, “patents 
have been used to narrow or clear the market of existing tests, thereby limiting, rather than 
promoting availability of testing.” Further, because the prices of genetic tests in the United 
States are driven by market forces, rather than rate-setting, U.S. patients were unable to pay 
for patented tests their insurance providers would not cover.13 This link between patents and 
prices was similarly raised in a recent dispute in Canada concerning genetic testing for 
familial long QT syndrome.14 
This disconnect between gene patents’ effects in the U.K. and elsewhere may have been 
partially tied to the patenting and licensing activities of a single company: Myriad Genetics 
and its patents covering BRCA1 and BRCA2, genes strongly implicated in early-onset breast 
and ovarian cancer. Unlike most other gene patent holders, Myriad Genetics both refused to 
outlicense its patents to other clinical laboratories and—shockingly—threatened to sue U.S. 
clinicians in the who were performing BRCA1 and BRCA2 sequencing at their own 
laboratories.5,15 This culminated in an advocacy suit against the company, seeking to invalidate 
gene patents on a large scale. In 2013, the Supreme Court of the United States decided an 
appeal from the case—Association for Molecular Pathology v. Myriad Genetics, Inc.—and ruled 
that gene patents covering “isolated human genomic DNA” were no longer eligible for patent 
protection.3 Parallel litigation concerning Myriad in Australia produced similar results against 
gene patenting. In 2015, the Australian High Court also ruled against Myriad, concluding that 
the company’s invention was “not ‘made’ by human action” but “discerned,” and therefore 
unpatentable.7 
The recent turn against patent eligibility for genes in the United States and Australia 
stands in contrast to the rest of the world. The 1998 European Council’s Biotech Directive 
affirmatively allowed the patenting of DNA sequences, so long as their patents disclosed their 
respective genes’ functions.16 This directive was later embodied in the European Patent 
Convention—to which the United Kingdom belongs independently of her association with 
the European Union. Rule 29 of the Implementing Regulations to the EPC reads that “the 
sequence or partial sequence of a gene, may constitute a patentable invention.”10 In addition, a 
2005 House of Lords decision interpreting the regulation, Kirin-Amgen v. Hoechst Marion 
Roussel, concluded that isolated and extracted DNA sequences were patentable inventions of 
their own.17 Much of the Commonwealth has decided similarly. Gene patents—again, in their 
isolated form—are still valid in Canada, where they were recently subject to litigation 
between Transgenomic, Inc. and the Children’s Hospital of Eastern Ontario.18,19  Today, gene 
patents remain alive and well in the U.K. and most of the world, but largely without the sort of 
exclusionary behavior propounded by Myriad Genetics rarer ever still.20 
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Gene Patents in Current Medicine 
Much of the early fear of gene patents stemmed from genetic sequencing’s nascency in 
medical practice. In the 1990s and early 2000s, diagnostic sequencing was generally ordered 
only for single-gene, Mendelian traits, and performed using DNA amplification and Sanger 
sequencing, technologies that required the creation of multiple, isolated copies of individual 
genes or gene fragments.20 This made diagnostic sequencing all the more likely to infringe on 
patents covering individual, isolated genes.6,8 Today, medical practice has adopted new forms 
of genetic sequencing and for a greater number of applications, including next-generation 
sequencing, therapeutic companion diagnostics, and prenatal genetic diagnosis. Like their 
predecessor technologies, the impact of traditional gene patents on these applications are 
likely to be muted. 
Next-Generation Sequencing 
Traditional diagnostic genetic sequencing was both burdensome and time intensive. The 
particular gene of interest was amplified using PCR, using gene-specific or, in some cases, 
allele specific primers. The resulting, amplified product, with radiolabeled terminal 
nucleotides evenly spread throughout the target gene, was then sorted by size via gel 
electrophoresis, and read either manually or by computer. This process, named Sanger 
sequencing after Frederick Sanger, who won the Nobel Prize in Chemistry for the technique 
in 1980, took hours if not days to complete and was prone to human error. In addition, because 
the process required the creation of isolated copies of the target gene, it put clinicians at risk 
for infringing gene patents: they were, in effect, “making” the patented gene without 
permission from the patent holder.6 
To date, Sanger sequencing has been largely replaced by “next-generation sequencing” 
technologies (NGS), a catch-all term describing a variety of automated, robust, multigene 
sequencing platforms. One of the more popular NGS platforms, Illumina sequencing, uses 
DNA randomly broken up into short segments, that are then “tagged” with adaptors and 
amplified. The resulting amplification products are then passed through a flow-cell, labeled 
with nucleotide specific fluorescent dyes, and read by machine. At the end, these reads are 
then reassembled into gene sequences using specialized software. Importantly, it is unlikely 
that a complete copy of an isolated gene is ever created. As a consequence, users of Illumina’s 
platforms are unlikely to infringe on traditional gene patents. Another NGS platform, 
nanopore  sequencing, does not even require amplification, and simply “reads” long stretches 
of DNA through an electrically sensitive molecular channel, i.e., a “nanopore.” Here, too, NGS 
technology is unlikely to infringe traditional gene patents.6 
While Sanger sequencing is still important for some applications, NGS technologies have 
largely supplanted them. Oxford University Hospitals NHS Foundation Trust, for example, 
now offers a suite of gene panel screens—multiple genes sequenced at once—all using NGS 
technologies.21 To date, the Trust offers at least 20 such panels—and there is no evidence, to 
date, that the development or use of any of these panels have been restricted or hampered by 
patents. In the U.S., several private companies—such as Exact Sciences and Foundation 
Medicine—each offer their own gene panel screens for different indications, and none of 
which appear to be embroiled in gene patent disputes. 
This is not to say that patents will not play a role in the development, pricing, and 
licensing of NGS. Indeed, Oxford Nanopore and Pacific Biosciences are currently embroiled 
in patent litigation in the United States over nanopore sequencing technology.22 Rather, gene 
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patents—patents covering specific nucleotide sequences—do not appear to have had a 
particularly significant on the medical establishment’s adoption or dissemination of these 
technologies. 
Therapeutic Companion Diagnostics 
Aside from traditional diagnostic testing, genetic diagnostics are also increasingly taking 
the form companion diagnostics, in vitro diagnostics (IVDs) to guide pharmaceutical 
treatment. The breast cancer antibody-drug conjugate Kadcyla (trastuzumab emtansine), for 
example, is indicated for patients with HER2-positive tumors. Physicians wishing to treat their 
patients with Kadcyla must screen biopsies for HER2 overexpression; a variety of tests are 
available from a number of UK testing centres as well as commercial providers.23,24 
Although the genetic sequencing of single genes to guide a course of treatment would 
seem to implicate gene patents, there is little evidence that gene patents have hindered 
companion sequencing. To the contrary, commercial developers of therapeutics that require 
companion sequencing tend to co-develop and then outsource sequencing to other providers, 
gene patents notwithstanding.25 This means that, frequently, after approval of the therapeutic 
product itself, related companion diagnostics tend to be offered by multiple providers. In 
Kadcyla’s case, HER2 testing has been offered by at least six commercial providers, none of 
which have attempted to enforce gene patents against the other.24 Depending on the 
therapeutic, doctors wishing to order companion diagnostics to guide treatment may have 
choices surrounding speed, accuracy, and cost. 
To be sure, patents still play an important role regarding IVDs. Many IVD providers have 
substantial patent portfolios and, in some instances, have not been shy about enforcing their 
patents against competitors. In the United States, Caris MPI recently sued Foundation 
Medicine on five patents covering the molecular profiling of certain tumors for 
chemotherapy.26 But such patents are typically directed not toward specific genetic sequences 
as much as methods of treatment conditioned on a collection of results derived from patients’ 
genetic profiling. As such, patents concerning companion diagnostics tend not to raise some 
of the more troubling issues concerning gene patents: they do not restrict research or 
diagnosis concerning all aspects of a given gene; they are often relatively narrow to specific 
gene panels and testing regimes, for which there may be alternatives; and they are frequently 
“industrial” enough to avoid ethical concerns surrounding the patenting of natural products. 
Here, too, gene patents—even where broadly applicable—do not appear restrict physician 
autonomy or patient access to treatment regimens. 
Prenatal Genetic Diagnostics 
Recently, medical practice has also widely adopted the use of prenatal genetic diagnostics, 
especially concerning the sequencing of maternal blood to detect fetal aneuploidies. Although 
several methods have been described, one popular method involves using NGS sequencing to 
sequence millions of short DNA tags extracted from maternal blood. The sequences of these 
tags are then aligned to various chromosomes along the human genome and quantified 
relative to a healthy, male reference sample. Overrepresentation of a particular chromosome, 
relative to other the chromosome’s “sequence tag density” in the control, suggests the 
presence of a fetal aneuploidy, such as those giving rise to Down, Edward, and Patau 
syndrome.27 
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Significantly, the technique does not rely on the sequencing of any genes in particular. 
Rather, “it can be applied to arbitrarily small fractions of fetal DNA,” as small as 25 base pairs 
in length—well short of the length of any human gene.27 As a consequence, the technique is 
unlikely to infringe on, or make use of, traditional gene patents. To that end, medical 
providers have seen substantial market evolution for such tests following their commercial 
introduction around 2012. By that time, four commercial providers were providing the test to 
practitioners—Sequenom, Verinata Health, Ariosa Diagnsotics, and Natera—prior to some 
recent market consolidation.28 
While gene patents have not stymied the introduction and development of prenatal 
genetic diagnostics, basic aspects of the technique itself was the subject of several 
foundational patents, held among competing entities. This has a triggered a hard-fought, 
costly, and still-litigated patent suit between Sequenom, now held by LabCorp, and Verinata, 
since acquired by Illumina.28 In addition, “[e]ven in the absence of market monopolies, IP-
related issues…could affect how tests are priced,” a potentially significant concern for NHS.29  
The patent situation concerning prenatal genetic diagnostics is therefore particularly 
nuanced. Foundational patents in this area do have the ability to control prices and access to a 
broad landscape of medically significant technology, much in the same way gene patents 
originally threatened to do. But unlike gene patents—which restrict physicians’ use of 
sequence information from a particular gene for any purpose—broad patents covering 
prenatal genetic diagnostics lock up only a particular technique that may, eventually, be 
supplanted, albeit with newly patented technologies. 
Patents and The Future of Genetic Medicine 
While gene patents appear to have only a muted effect on current medical practices, they 
seem similarly quiet on future practices—namely, whole genome sequencing, precision 
medicine, and genetic engineering. Like current genetic diagnostics, these technologies do not 
depend on the isolation and amplification of individual human genes, the fulcrum to gene 
patents’ force. Instead, they typically rely on large-scale, gene-independent sequencing, and, 
in the case of genetic engineering, the creation of synthetic sequences unlikely to be covered 
by traditional gene patents.  
These future technologies, however, are not free from patent controversies. Each has been 
the subject of broad patents covering important implementations of the technology; some of 
these have been litigated vigorously between competitors. Thus, while gene patents may have 
a muted effect on the next generation of genetic medicine, the future adoption of these 
technologies in medical practice may depend on more technologically focused patents. 
Whole Genome Sequencing 
Since the completion of the Human Genome Project in 2003, commentators have 
advocated for whole genome sequencing (WGS) to become part of the medical canon.30 First 
viewed as an impractical, quixotic luxury, the cost of WGS has now dropped to about £750, 
and is continuing to fall. 31  In addition, WGS—even with some significant technical 
limitations—has been demonstrated to be clinically useful in detecting some cardiac 
pathologies, as well as diabetes and cancer risk.30 Today, companies such as Ambry, Counsyl 
and InVitae now offer competitively priced WGS, and no patent holder appears to have tried 
to obstruct WGS on the basis of single gene patents.32 
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But, like many revolutionary technologies, WGS is subject to what have essentially 
become standards wars—disputes over foundational, technological standards—mediated 
through patent litigation among NGS companies. In addition to the dispute between PacBio 
and Oxford Nanopore,22 there are also lawsuits among Illumina, Complete Genomics, Helicos, 
Intelligent Bio-Systems, Ion Torrent, and Roche.33 Cost and access to WGS may be affected by 
the outcome of these disputes.33 And, because each WGS technology operates slightly 
differently—with different limitations concerning what it can and cannot detect30—these 
patent disputes may ultimately drive how far WGS is clinically available. 
Precision Medicine 
Precision medicine can be defined as “precisely tailored therapies to subcategories of 
disease, often defined by genomics.”34 That is, rather than diagnosing and treating patients 
from constellation of symptoms—as physicians have done for millennia—doctors may utilize 
precision medicine to prescribe therapies on the basis of genetic diagnostics.35 These include 
treatments that are, themselves, indicated and approved for genetic markers rather than 
diagnoses of disease. Recent therapeutic advances in precision medicine include, Keytruda 
(pembrolizumab),  Kymriah (tisagenlecleucel),  and Alnylam’s forthcoming patisiran RNA 
therapy product.36  
These therapeutic products seem neither to rely on nor are stymied by individual gene 
patents. While each does require the sequencing of individual genes, like companion 
diagnostics, to date, no precision therapy appears to have been held back from clinical 
investigation or regulatory approval due to the assertion of patents covering individual genes.  
Nonetheless, patents appear to have had a significant effect on the development of 
precision therapies. Precision medicine often derives from fundamental research originally 
sited at universities, many of which seek patent protection on their contributions and then 
later engage in restrictive licensing practices. These have the capacity to bottleneck further 
research, as well as increase cost, shape development, and limit patient access.37-38 Thus, while 
it is unlikely that gene patents will guide the future course of precision therapies, they may 
very well turn on how their related patents are licensed and enforced.36 
Genetic Engineering 
Lastly, genetic engineering holds substantial promise for the future of medical practice, 
with the potential to treat patients by permanently repairing their underlying genetic 
etiologies. Recent advances, such as the much-hyped gene-editing system, CRISPR, as well as 
zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), 
have shown strong potential in both laboratories and preclinical trials. 39  Even older 
technologies, such as permanently stable DNA delivered through adeno-associated viruses 
(AAVs), have demonstrated recent successes, as with Spark Therapeutics’ recent U.S. 
approval of Luxturna (voretigene neparvovec-rzyl). 
Because most of these technologies rely on the creation of synthetic nucleotide sequences, 
they, too, do not seem to be affected by traditional gene patents. But they are often the subject 
of broad, foundational patents in the area that may squelch competition much as gene patents 
were once feared to do. Famously, basic forms of using CRISPR are the subject of a 
particularly contentious patent dispute between the University of California, Berkeley and the 
Broad Institute, that has yet to be resolved. The resolution of that dispute is likely to affect the 
ownership over vast swaths of clinically useful applications of CRISPR, and may ultimately 
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impede on physician and patient choice by modulating pricing, coverage, and regulation of 
the technique.40 
Conclusion 
Although gene patents—however defined—have captured the medical profession’s 
collective imagination, recent developments in law, medicine, and technology have muted 
their effects. While gene patents remain valid in the United Kingdom, they do not appear to 
have had a strong effect on medical decision-making or access to genetic tests. Elsewhere, 
earlier attempts to stringently enforce single-gene patents against clinicians have either been 
rare or effectively hobbled. Additionally, medicine’s current use of genetic testing—through 
next-generation sequencing, therapeutic companion sequencing, or prenatal genetic 
diagnostics—does not appear to come within the scope of traditional gene patents. Nor do 
newer genetic technologies and applications, such as whole genome sequencing, precision 
medicine, and genetic engineering. This is not to say that genetics, writ large, has moved 
beyond patent protection. To the contrary, some of these technologies lay as spoils in 
particularly fevered patent disputes between rivals. And the outcome of these disputes will 
likely have significant effects on patient access and physicians’ choice of diagnostics and 
treatments. Patents may still significantly shape medical practice. But those patents will not be 
on isolated genes. 
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